Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT06343402

Public ClinicalTrials.gov record NCT06343402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.

Study identification

NCT ID: NCT06343402
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Enrollment: 350 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 21, 2024
Primary completion: Mar 31, 2031
Completion: Aug 31, 2031
Last update posted: Sep 2, 2026

2024 – 2031

United States locations

U.S. sites: 23
U.S. states: 16
U.S. cities: 22

Facility	City	State	ZIP	Site status
O'Neal Comprehensive Cancer Center at UAB	Birmingham	Alabama	35233	Recruiting
University of California - San Diego Moores Cancer Center	La Jolla	California	92093	Recruiting
University of California San Francisco	San Francisco	California	94158	Recruiting
UCLA Health - Santa Monica Cancer Care	Santa Monica	California	90404	Recruiting
University of Colorado Cancer Center	Aurora	Colorado	80045	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
Norwalk Hospital	Norwalk	Connecticut	06850	Recruiting
OSF Saint Francis Medical Center	Peoria	Illinois	61603	Recruiting
University of Kansas Medical Center	Kansas City	Kansas	66205	Recruiting
University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center	Baltimore	Maryland	21201	Recruiting
Henry Ford Cancer - Detroit	Detroit	Michigan	48282	Recruiting
Roswell Park Cancer Institute	Buffalo	New York	14263	Recruiting
Perlmutter Cancer Center - NYU Langone Health	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
USOR - Oncology Associates of Oregon, P.C	Eugene	Oregon	97401	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
Oncology Consultants Texas Medical Center	Houston	Texas	77030	Recruiting
USOR - Texas Oncology - (DFW) Waco	Waco	Texas	76710	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting
NEXT Oncology	Fairfax	Virginia	22031	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting
Northwest Medical Specialties	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06343402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 2, 2026 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06343402 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →